Selinexor (KPT-330) is a new XPO1 inhibitor and is an effective small-molecule drug with promising antitumor effects in various human tumors, including AML in vitro and in vivo [23,25,26,27]. The gene discussed is XPO1; the disease is acute myeloid leukemia.